Leslie M. Randall

Leslie M. Randall

Oncology | Obstetrics and Gynecology

8081 Innovation Park Dr
775
Fairfax, VA 22031

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.

Journal: JCO precision oncology

Published: August 26, 2026

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 19, 2026

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.

Journal: Gynecologic oncology

Published: February 02, 2026

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer.

Journal: NPJ precision oncology

Published: November 21, 2025

A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer.

A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: August 20, 2025

Prognostic value of FDG-PET SUV changes in cervical cancer following radiation therapy: a retrospective cohort study.

Prognostic value of FDG-PET SUV changes in cervical cancer following radiation therapy: a retrospective cohort study.

Journal: Archives of gynecology and obstetrics

Published: July 04, 2025

Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New Investigator Program.

Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New Investigator Program.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 08, 2025

Correction: Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.

Correction: Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.

Journal: PloS one

Published: May 20, 2025

Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy.

Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy.

Journal: JAMA network open

Published: May 15, 2025

The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution.

The GOG Foundation and EVA/LACOG partnership: a collaborative strategic alliance for clinical trial execution.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 18, 2025

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.

Journal: Gynecologic oncology

Published: March 10, 2025

ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.

ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: December 11, 2024

Showing 1-12 of 75

Last Updated: 09/26/2026